Mesobiliverdin IXα ameliorates osteoporosis via promoting osteogenic differentiation of mesenchymal stem cells

Biochem Biophys Res Commun. 2022 Sep 3:619:56-61. doi: 10.1016/j.bbrc.2022.06.042. Epub 2022 Jun 15.

Abstract

Heme oxygenase-1 (HO-1) expression promotes osteogenesis, but the mechanisms remain unclear and therapeutic strategies using it to target bone disorders such as osteoporosis have not progressed. Mesobiliverdin IXα is a naturally occurring bilin analog of HO-1 catalytic product biliverdin IXα. Inclusion of mesobiliverdin IXα in the feed diet of ovariectomized osteoporotic mice was observed to increase femur bone volume, trabecular thickness and osteogenesis serum markers osteoprotegrin and osteocalcin and to decrease bone resorption serum markers cross-linked N-teleopeptide and tartrate-resistant acid phosphatase 5b. Moreover, in vitro exposure of human bone marrow mesenchymal stem cells to mesobiliverdin IXα enhanced osteogenic differentiation efficiency by two-fold over non-exposed controls. Our results imply that mesobiliverdin IXα promotes osteogenesis in ways that reflect the potential therapeutic effects of induced HO-1 expression in alleviating osteoporosis.

Keywords: Heme oxygenase-1; Mesenchymal stem cell; Mesobiliverdin; Osteoblast; Osteogenic differentiation; Ovariectomized osteoporotic mouse.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Biliverdine / analogs & derivatives
  • Biomarkers / metabolism
  • Cell Differentiation
  • Cells, Cultured
  • Humans
  • Mesenchymal Stem Cells*
  • Mice
  • Osteogenesis
  • Osteoporosis* / drug therapy
  • Osteoporosis* / metabolism

Substances

  • Biomarkers
  • mesobiliverdin
  • Biliverdine